REFERENCES
- Andersen JT, Nickel JC, Marshal VR (1997): Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839–845.
- Boyle PP, Siami P, Wachs BH (2002): Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment. J Urol 167:372–378.
- Boyle P, Roehrborn C, Marks L (2003): Early use of dutasteride arrests prostate growth, improves clinical parameters and prevents complications in men with benign prostatic hyperplasia. J Urol 169:477–482.
- Brooks JR, Berman C, Garnes D (1986): Prostatic effects induced in dogs by chronic or acute oral administration of 5α-reductase inhibitors. Prostate 9:65–69.
- Clark RV, Hermann DJ, Gabriel H ( ?): Almost complete suppression of dihydrotestosterone in men with BPH by GII98745, a novel, dual 5-alpha-reductase inhibitor. , North Carolina: GlaxoSmith Kline ( unpublished data: 2000 March).
- Evans HC, Goa KL (2003): Dutasteride. Drugs Aging 20:905–916.
- Finasteride Study Group (1993): Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291–299.
- Gisleskog PO, Hermann D, Hammarlund-Udenaes M (1998): A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GII98745 and finasteride. Clin Pharmacol Ther 64:636–647.
- Gormley GJ, Stoner E, , et al. (1992): The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327:1185–1191.
- Griffin JE, Wilson JD (1985): Disorders of the testes and male reproductive tract. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW, (Eds). Philadelphia: WB Saunders, p 259.
- Hermann DJ, Wilson TH, Morill BB (1997): A 28-day evaluation of GII98745, a potent dual 5-alpha reductase inhibitor, in BPH patients. J Urol 157(4suppl):315–319.
- Jenkins EP, Andersson S, , et al. (1992): Genetic and pharmacological evidence for more than one human steroid 5alfa-reductase. J Clin Invest 89:293–300.
- Liang T, Heiss CE, Cheung AH (1982): 4-Azasteroid-5α-reductase inhibitors without affinity for the androgen receptor. J Biochem 259:734.
- O'Leary MP, Roehrborn C, Andriole G (2003): Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 92:262–266.
- Rittimaster RS, Stoner E, Thompson DL (1989): Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 10:259.
- Roehrborn CG, Boyle P, Nickel JC (2002): Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. ARIA 3001, ARIA 3002 and ARIA 3003 study investigators. Urology 60:434–441.
- Roehrborn C, Ramsdell J, Siami P (2002): Prostate volume at baseline predicts the margin of therapeutic response with the 5α-reductase inhibitor, dutasteride. J Urol 167 suppl:373–379.
- Silver RI, Wiley EI, , et al. (1994): Cell type specific expression of steroid 5alfa-reductase 2. J Urol 152:438–442.
- Thigpen AE, Davis DL, , et al. (1992): Molecular genetics of steroid 5alfa-reductase 2 deficiency. J Clin Invest 90:799–809.
- Thigpen AE, Silver RI, , et al. (1993): Tissue distribution and ontogeny of steroid 5alfa-reductase isoenzyme expression. J Clin Invest 92:903–910.
- Vermeulen A, Giagulli VA, Schepper PD (1989): Hormonal effects of an orally active 4-azasteroid inhibitor or 5α-reductase in humans. Prostate 14:45.